Drug Insights

Navigating Health Information: How to Use Synapse to Search for Hydroxyzine

31 January 2024
2 min read

Hydroxyzine is a first-generation antihistamine that is commonly used for the treatment of various allergic conditions such as hives and itching. It works by blocking the action of histamine, a chemical released in response to an allergic reaction. Histamine causes symptoms such as itching, swelling, and rash. Hydroxyzine is available in oral and injectable formulations. It is generally well tolerated by patients. However, side effects can include drowsiness, dizziness and dry mouth. It is important to note that there is ongoing research regarding the potential use of hydroxyzine to treat anxiety disorders, as it has shown some anxiolytic activity in preclinical studies. Click on the image below to begin the exploration journey of Hydroxyzine through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Fentanyl
Drug Insights
2 min read
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Fentanyl
31 January 2024
Fentanyl, a tiny molecule drug, is a COX-2 inhibitor that specifically targets the COX-2 enzyme causing inflammation and pain.
Read →
Opdivo and CABOMETYX Exhibit Long-Term Survival in 4-Year CheckMate-9ER Trial for Advanced RCC
Latest Hotspot
3 min read
Opdivo and CABOMETYX Exhibit Long-Term Survival in 4-Year CheckMate-9ER Trial for Advanced RCC
31 January 2024
Opdivo® (nivolumab) and CABOMETYX® (cabozantinib) Show Long-Term Survival in 4-Year CheckMate-9ER Trial for 1st-Line Advanced RCC.
Read →
The Synapse User's Toolkit: Tips for Searching Meloxicam
Drug Insights
2 min read
The Synapse User's Toolkit: Tips for Searching Meloxicam
31 January 2024
Meloxicam, a small molecule drug, is a COX-2 inhibitor that targets the enzyme causing inflammation and pain.
Read →
Scholar Rock Receives FDA Approval for Phase 2 Obesity Trial with Apitegromab
Latest Hotspot
3 min read
Scholar Rock Receives FDA Approval for Phase 2 Obesity Trial with Apitegromab
31 January 2024
Scholar Rock Reveals U.S. FDA Approval for Phase 2 Trial Commencement, Testing Apitegromab for Obesity Management.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.